Patents by Inventor James Lorens

James Lorens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230372337
    Abstract: This disclosure relates to a combination therapy for treating patients suffering from a proliferative disease. More particularly, the disclosure relates to combination therapies comprising an AXL inhibitor, an immune checkpoint modulator (ICM), and a chemotherapeutic agent and/or radiotherapy for treating patients suffering from cancer, as well as compositions and methods for treating patients with said combination therapy.
    Type: Application
    Filed: March 23, 2021
    Publication date: November 23, 2023
    Applicant: BERGENBIO ASA
    Inventor: James LORENS
  • Publication number: 20230151100
    Abstract: The invention relates to a method of selecting a subject for treatment with a combination of an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM), the method comprising: identifying subjects having an AXL-related disease characterised by the presence of cells having modified STK11 activity or expression; and, selecting thus identified subjects for treatment. The invention also relates to an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM) for use in the treatment of an AXL-related disease.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 18, 2023
    Applicants: BERGENBIO ASA, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James LORENS, David MICKLEM, Huiyu LI, Zhida LIU, John MINNA, Rolf BREKKEN
  • Patent number: 9783801
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: October 10, 2017
    Assignee: BerGenBio ASA
    Inventors: David Micklem, James Lorens
  • Publication number: 20140194322
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Application
    Filed: December 10, 2013
    Publication date: July 10, 2014
    Applicant: BerGenBio AS
    Inventors: DAVID MICKLEM, JAMES LORENS
  • Patent number: 8735064
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: May 27, 2014
    Assignee: Bergenbio AS
    Inventors: David Micklem, James Lorens
  • Patent number: 8334238
    Abstract: The invention relates to novel methods of detecting alterations in cell cycle regulation in a cell or a cell population and screening for agents capable of modulating cell cycle regulation through the use of multiparameter assays and a fluorescence-activated cell sorter (FACS) machine.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: December 18, 2012
    Assignee: Rigel, Inc.
    Inventors: Joseph Fisher, James Lorens, Donald Payan, Alexander Rossi
  • Publication number: 20110009281
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Application
    Filed: December 23, 2008
    Publication date: January 13, 2011
    Inventors: David Micklem, James Lorens
  • Patent number: 7566546
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Sacha J. Holland, Weiduan Xu
  • Patent number: 7527936
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: May 5, 2009
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Weiduan Xu, Sacha J. Holland, James Lorens
  • Publication number: 20070172818
    Abstract: The invention relates to novel methods of detecting alterations in cell cycle regulation in a cell or a cell population and screening for agents capable of modulating cell cycle regulation through the use of multiparameter assays and a fluorescence-activated cell sorter (FACS) machine.
    Type: Application
    Filed: December 7, 2006
    Publication date: July 26, 2007
    Inventors: Joseph Fisher, James Lorens, Donald Payan, Alexander Rossi
  • Publication number: 20070166769
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Application
    Filed: March 7, 2007
    Publication date: July 19, 2007
    Inventors: James Lorens, Jakob Bogenberger
  • Publication number: 20070105140
    Abstract: The present invention relates to methods and compositions utilizing inteins to generated libraries of cyclic peptides in vivo.
    Type: Application
    Filed: October 4, 2006
    Publication date: May 10, 2007
    Inventors: James Lorens, Todd Kinsella, Todd Pray, Mark Bennett
  • Patent number: 7205130
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 17, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Jakob M. Bogenberger
  • Publication number: 20060264392
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic adds, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: September 2, 2003
    Publication date: November 23, 2006
    Inventors: James Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
  • Publication number: 20060147978
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Application
    Filed: February 24, 2006
    Publication date: July 6, 2006
    Inventors: James Lorens, Todd Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Liao, Denise Pearsall, Annabelle Friera, Peter Chu
  • Patent number: 7056687
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: June 6, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Todd M. Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Charlene Liao, Denise Pearsall, Annabelle Freiro, Peter Chu
  • Publication number: 20050260626
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Application
    Filed: February 28, 2005
    Publication date: November 24, 2005
    Inventors: James Lorens, Todd Pray, Todd Kinsella, Mark Bennett
  • Publication number: 20050250163
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: February 16, 2005
    Publication date: November 10, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Sacha Holland, Weiduan Xu
  • Publication number: 20050208472
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: January 13, 2005
    Publication date: September 22, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Weiduan Xu, Sacha Holland, James Lorens
  • Publication number: 20050118604
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: October 29, 2003
    Publication date: June 2, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Robert Atchison, Annabelle Friera, Sacha Holland